Cancer Biopsy Market Report 2026

The cancer biopsy market size has grown rapidly in recent years. It will grow from $28.52 billion in 2025 to $32.41 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing global cancer incidence, expansion of diagnostic imaging facilities, adoption of tissue biopsy as standard diagnostic practice, growth of pathology laboratory networks, improvements in biopsy device technologies.

The cancer biopsy market size is expected to see rapid growth in the next few years. It will grow to $53.38 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, rising adoption of liquid biopsy testing, expansion of personalized cancer treatment planning, growing investments in molecular diagnostics, increasing focus on early-stage cancer screening. Major trends in the forecast period include increasing adoption of liquid biopsy techniques, rising use of image-guided biopsy procedures, growing integration of molecular pathology testing, expansion of minimally invasive biopsy devices, enhanced focus on early cancer detection.

The rising prevalence of cancer is expected to drive growth in the cancer biopsy market in the coming years. Cancer is a complex group of diseases characterized by the abnormal growth and spread of cells. Its increasing incidence is influenced by factors such as lifestyle changes, urbanization, environmental pollution, tobacco and alcohol consumption, healthcare access, and awareness. Cancer biopsies are used to diagnose and evaluate the type, stage, and spread of cancer by extracting and analyzing tissue or cells from suspicious areas. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, over 35 million new cancer cases would occur, representing a 77% increase compared to an estimated 20 million cases in 2022. Consequently, the rising prevalence of cancer is driving the cancer biopsy market.

Leading companies in the cancer biopsy market are developing liquid biopsy techniques to enable non-invasive early detection and monitoring of cancer, improve patient outcomes, and support more personalized treatment approaches. Liquid biopsy is an advanced, non-invasive diagnostic method that detects and analyzes genetic material from blood samples, including circulating tumor DNA (ctDNA), RNA, exosomes, and other biomarkers. For instance, in May 2023, Labcorp, a US-based manufacturer of cancer biopsy solutions, launched Labcorp Plasma Focus, a plasma-focused liquid biopsy for detecting cancer-related biomarkers. The Plasma Focus test analyzes circulating cell-free DNA (cfDNA) released from tumor cells into the bloodstream and constructs a genomic profile of the patient’s tumor, identifying mutations across 33 genes associated with cancers such as non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

In June 2023, Quest Diagnostics, a US-based provider of diagnostic information services, acquired Haystack Oncology for up to $450 million. This acquisition aims to strengthen Quest Diagnostics’ expertise in cancer diagnostics, particularly in minimal residual disease (MRD) detection. Haystack Oncology is a US-based company specializing in liquid biopsy technology for cancer detection.

Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc.

North America was the largest region in the cancer biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cancer biopsy market by increasing costs of imported biopsy needles, imaging guidance systems, molecular testing kits, and laboratory analysis equipment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported diagnostic devices, while Asia-Pacific faces higher costs for consumables and testing reagents. These tariffs are raising diagnostic procedure costs and extending procurement cycles. However, they are also encouraging domestic manufacturing of biopsy devices, regional reagent production, and local innovation in oncology diagnostics.

The cancer biopsy market research report is one of a series of new reports that provides cancer biopsy market statistics, including cancer biopsy industry global market size, regional shares, competitors with a cancer biopsy market share, detailed cancer biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biopsy industry. This cancer biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A cancer biopsy is a medical procedure that involves removing a small sample of tissue or cells from a suspicious area of the body to determine the presence of cancer or other conditions. This procedure is crucial for cancer diagnosis, as imaging techniques such as computed tomography (CT) scans or magnetic resonance imaging (MRI) cannot definitively distinguish between cancerous and non-cancerous cells.

The primary types of cancer biopsies include tissue biopsies, liquid biopsies, and others. Tissue biopsies involve extracting a small sample of tissue for microscopic examination. They are used in the diagnosis of various cancers, including breast, colorectal, cervical, lung, prostate, skin, blood, and kidney cancers, among others. The main end users of cancer biopsy procedures include hospitals, diagnostic laboratories, and other healthcare facilities.

The cancer biopsy market consists of sales of biopsy needles, biopsy guns, and biopsy punches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.